Schizophrenia & Psychosis
Top Stories
-
Source:
Psychiatric Times
“Our findings open the door for the development of treatments to target specific symptoms of psychosis depending on an individual subject’s symptom profile," says Guillermo Horga, MD, PhD
-
Source:
Psychiatric Times
Dr. Joshua Kantrowitz discusses a recent trial of CVN058, a drug that may reduce cognitive impairments in individuals with schizophrenia.
-
Columbia researchers have found a potential neurobiological mechanism for hallucinations and delusions that fits within the hierarchical model of psychosis and can explain their clinical presentation
-
Dr. Ragy Girgis speaks about the benefits of treating those with psychosis early in their illness.
Latest News
-
Dr. Gary Brucato, the Center of Prevention and Evaluation's Assistant Director, breaks down some of the early warning signs and symptoms of possible emergent psychotic illness.
-
Source:
Psychiatry & Behavioral Health Learning Network
This study “adds to a growing literature of using electrophysiological outcomes, including mismatch negativity as predictive biomarkers,” commented Dr. Joshua Kantrowitz.
-
In this first episode of Inside Schizophrenia, Rachel Star Withers, a diagnosed schizophrenic, co-host Gabe Howard and special guest Dr. Ali Mattu explore this often misrepresented mental illness.
-
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
-
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
-
A new study from Columbia University and New York State Psychiatric Institute offers insight into the development of delusions, which could lead to better treatments for people with psychosis.
-
“What happens that leads people to relapse is that many don’t want to stay on medication and they’re not adherent,” says Dr. Jeffrey A. Lieberman.
-
"I expect that clinicians will change their practices by prescribing fewer benzodiazepines and more antidepressants for people with schizophrenia," Dr. T. Scott Stroup said.
-
Schizophrenia and other psychotic disorders affect each person differently and vary in severity, said Dr. Lisa Dixon.
-
“The effectiveness of combinations of antipsychotic medications remains unclear; reviews of this treatment strategy agree on the need for further investigation,” Dr. T. Scott Stroup and team wrote.
Pages